文献速递细菌感染、耐药与抗菌药物

囊性纤维化患者开始使用Elexacaftor-Tezacaftor-Ivacaftor后感染相关就诊和抗菌药物使用的快速减少

The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor.
PubMed 文献 · Clin Infect Dis · 2022-01-01

利用IBM MarketScan数据纳入389名开始使用ELX/TEZ/IVA的囊性纤维化患者,比较用药前15周与后15周结局。病例交叉分析显示感染相关就诊次数变化-0.62(95%CI -0.93至-0.31),抗生素处方变化-0.78(95%CI -1.03至-0.54);双重差分分析结果相似。结论为开始该治疗后感染相关就诊和抗菌药物使用快速减少。

要点

  • 开始ELX/TEZ/IVA后15周内感染相关就诊次数变化为-0.62(95%CI -0.93至-0.31)。
  • 开始ELX/TEZ/IVA后15周内抗生素处方变化为-0.78(95%CI -1.03至-0.54)。
  • 该治疗并非专门针对感染设计,但感染相关就诊和抗菌药物使用快速减少。

核心结论

  • 在开始并非专门针对感染设计的ELX/TEZ/IVA治疗后,囊性纤维化患者的感染相关就诊和抗菌药物使用快速减少。
  • 鉴于该治疗对约90%的囊性纤维化患者有效,其对呼吸道感染和抗菌药物使用的影响可能很大。

研究设计与样本

  • 利用IBM MarketScan数据识别389名开始使用ELX/TEZ/IVA的囊性纤维化参保者,开始用药时间在2019年12月1日之前,参保时间为2019年7月1日至2020年3月14日。
  • 同时识别研究期间未开始使用ELX/TEZ/IVA的对照人群。
  • 比较用药开始前15周与后15周的总就诊、住院就诊、感染相关就诊和抗菌药物处方,采用病例交叉分析和双重差分分析控制潜在趋势。

主要发现

  • 病例交叉分析中,开始ELX/TEZ/IVA与15周期间总体就诊日期变化-2.5(95%CI -3.31至-1.7)相关。
  • 住院入院变化-0.16(95%CI -0.22至-0.10)。
  • 感染相关就诊日期变化-0.62(95%CI -0.93至-0.31)。
  • 抗生素处方变化-0.78(95%CI -1.03至-0.54)。
  • 双重差分分析结果与病例交叉分析相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with cystic fibrosis (CF) routinely suffer from recurrent sinopulmonary infections. Such infections require frequent courses of antimicrobials and often involve multidrug-resistant organisms. The goal of this study was to identify real-world evidence for the effectiveness of elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) in decreasing infection-related visits and antimicrobial use in people with CF. METHODS: Using IBM MarketScan data, we identified 389 enrollees with CF who began taking ELX/TEZ/IVA before 1 December 2019 and were enrolled from 1 July 2019 to 14 March 2020. We also identified a comparison population who did not begin ELX/TEZ/IVA during the study period. We compared the following outcomes in the 15 weeks before and after medication initiation: total healthcare visits, inpatient visits, infection-related visits, and antimicrobial prescriptions. We analyzed outcomes using both a case-crossover analysis and a difference-in-differences analysis, to control for underlying trends. RESULTS: For the case-crossover analysis, ELX/TEZ/IVA initiation was associated with the following changes over a 15-week period: change in overall healthcare visit dates, -2.5 (95% confidence interval, -3.31 to -1.7); change in inpatient admissions, -0.16 (-.22 to -.10); change in infection-related visit dates, -0.62 (-.93 to -.31); and change in antibiotic prescriptions, -0.78 (-1.03 to -.54). Results from the difference-in-differences approach were similar. CONCLUSIONS: We show a rapid reduction in infection-related visits and antimicrobial use among people with CF after starting a therapy that was not explicitly designed to treat infections. Currently, there are >30 000 people living with CF in the United States alone. Given that this therapy is effective for approximately 90% of people with CF, the impact on respiratory infections and antimicrobial use may be substantial.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Miller AC, Harris LM, Cavanaugh JE, et al. The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor. Clin Infect Dis. 2022. PMID: 35142340. doi:10.1093/cid/ciac117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。